According to survey results presented at ASHG, most genetics experts support somatic and germline gene editing, though few favor trait enhancement.
There are signs that doctors may be moving away from experimental precision therapy options in favor of immunotherapy and the chance at longer survival.
In a survey of 132 oncologists, Medscape tracked how they are using next-generation sequencing and what they think of its clinical utility.
There is significant interest in technologies that provide long-range genomic information, but only among a subset of users.
Only 5 percent of respondents said they got tested through a consumer genomics firm, but the future market could be worth as much as $7 billion, analysts at UBS estimated.
Researchers examined the patient-physician relationship after sharing personal genetic testing results and found that patients may have certain expectations.
A Vanderbilt University survey revealed most clinicians don't need convincing PGx testing is useful, but they don't agree which provider is responsible for the next step.
Around 70 percent of cancer compounds and 40 percent of compounds for all indications are being developed with biomarker data.
Poor patient health, tumor histology, insufficient tissue samples, and long turnaround times are some reasons doctors gave for not using EGFR status to determine care.
The survey, conducted by GenomeWeb in conjunction with investment bank William Blair, found that users operate their NGS instruments at different capacities.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.